STANDARD_NAME FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN SYSTEMATIC_NAME M10389 COLLECTION C2:CGP MSIGDB_URL https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN NAMESPACE AFFY_HG_U95 DESCRIPTION_BRIEF Genes down-regulated in B-CLL (B-cell chronic lymphocytic leukemia) patients with mutated immunoglobulin variable heavy chain (VH) genes. DESCRIPTION_FULL The usage of the immunoglobulin (Ig) V(H)3-21 gene is associated with poor prognosis in B-cell chronic lymphocytic leukemia (B-CLL) despite V(H) gene mutation status. Many V(H)3-21+ patients also display restricted heavy- and light-chain Ig gene rearrangements, implying a role of antigen selection in disease development. To explore the specific phenotypic/genotypic features among V(H)3-21+ B-CLLs, we compared gene expression patterns in 15 V(H)3-21+ and 24 non-V(H)3-21 patients (11 with unmutated and 13 with mutated V(H) genes) using Affymetrix microarray analysis (approximately 12,500 genes). A distinct expression profile was identified for V(H)3-21+ patients in contrast to the Ig-unmutated and -mutated groups. By applying different algorithms, the data enabled an efficient class discrimination of the V(H)3-21+ subset based on 27 or 57 genes. A set of genes was sorted out which, using different analytical methods, consistently gave a distinction between V(H)3-21+ and non-V(H)3-21 samples. Several of these genes are involved in regulation of DNA replication/cell-cycle control, transcription and protein kinase activity, which may render the V(H)3-21+ cells with a higher proliferative drive. However, no clear evidence of increased B-cell receptor signaling was found in the V(H)3-21+ group. Altogether, our identification of a specific V(H)3-21 profile may provide insights into the pathogenesis of the V(H)3-21+ subgroup. PMID 15817677 GEOID AUTHORS Fält S,Merup M,Tobin G,Thunberg U,Gahrton G,Rosenquist R,Wennborg A CONTRIBUTOR Kevin Vogelsang CONTRIBUTOR_ORG MSigDB Team EXACT_SOURCE Table 2S FILTERED_BY_SIMILARITY EXTERNAL_NAMES_FOR_SIMILAR_TERMS EXTERNAL_DETAILS_URL SOURCE_MEMBERS 1480_at,31506_s_at,32530_at,32584_at,32696_at,32745_at,32847_at,33394_at,33835_at,33865_at,34043_at,34192_at,34767_at,34782_at,34859_at,34860_g_at,355_s_at,36002_at,36128_at,36188_at,36201_at,36489_at,36502_at,36553_at,36620_at,36894_at,36948_at,37303_at,37663_at,37729_at,38005_at,38485_at,38610_s_at,38654_at,38814_at,38820_at,38837_at,38839_at,38993_r_at,39088_at,39175_at,39756_g_at,39967_at,40410_at,41488_at,41503_at,41796_at,812_at,832_at,891_at GENE_SYMBOLS HSPA4,DEFA1,YWHAQ,PSMD8,PBX3,MRPL40,MYLK,DDX19A,TSPYL4,ZMYND11,ADTRP,VPS13B,MOAP1,JARID2,MAGED2,MAGED2,FKBP1B,TRAPPC8,TMED10,GTF3A,GLO1,PRPS1,CDK14,ASMTL,SOD1,CBX7,EID1,PARP4,DDX1,XPO1,SLC35D2,NDUFC1,KRT10,HNRNPU,ATP6V1G1,SELENOF,TMX4,PFN2,TGOLN2,TMEM147,PFKP,XBP1,LDOC1,DCTN3,LYRM1,ZHX2,PLCL2,PPP1R2,UBE2D2,YY1 FOUNDER_NAMES